The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans

The insulin-sensitizer pioglitazone exerts its cardiometabolic benefits in type 2 diabetes (T2D) through a redistribution of body fat, from ectopic and visceral areas to subcutaneous adipose depots. Whereas excessive weight gain and lipid storage in obesity promotes insulin resistance and chronic in...

Descripción completa

Detalles Bibliográficos
Autores principales: Palavicini, Juan P., Chavez-Velazquez, Alberto, Fourcaudot, Marcel, Tripathy, Devjit, Pan, Meixia, Norton, Luke, DeFronzo, Ralph A., Shannon, Christopher E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674727/
https://www.ncbi.nlm.nih.gov/pubmed/34925073
http://dx.doi.org/10.3389/fphys.2021.784391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674727/
https://www.ncbi.nlm.nih.gov/pubmed/34925073
http://dx.doi.org/10.3389/fphys.2021.784391

Ejemplares similares